Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 878 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR 如何捐赠头发来帮助癌症患者 April 13, 2022 A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... August 29, 2023 A winding journey into the world of children’s and young people’s... September 24, 2021 Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK December 21, 2020 Load more HOT NEWS No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and... Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... This Common Antibiotic May Help Support Immune System in Cancer Patients... How MRI add-ons could accelerate the development of new treatments
